MXIS DEVELOPMENT 
TARGET

2024

Milestones of innovative drugs and new quality

August: Application for production of the new anti influenza drug Mapasvir;

             TSLP monoclonal antibody completes the first phase II subject enrollment

October: The first subject enrolled in phase II of GSNOR inhibitor was completed

November: The first subject enrolled in Phase II of the MABA dual target project was completed

December: PREP oral COPD project received IND clinical approval

2022

Accelerate the research and development of innovative drugs and high-end complex formulations, and promote the process of globalization

On September 2, 2022, after being recommended by the National Health Commission, the National Medical Products Administration organized a discussion and agreed to accept the use of Likang V-01
Emergency use of sequential enhanced immunization against novel coronavirus.

On September 26th, the group successfully listed and issued Global Depositary Receipts (GDRs) on the Swiss Stock Exchange, becoming the first domestic biopharmaceutical company to issue GDRs in Switzerland and accelerating the process of globalization.

On October 15th, the group's first independently developed tobramycin inhalation solution (i.e. Jianketuo) ®) Formally approved for listing, it also announced the birth of the first inhaled antibiotic in China and even globally. We will change the current situation of no available medication in the field of nebulized inhalation therapy for patients with bronchiectasis in China, and provide more support for patients with bronchiectasis.

Starting from 2018

Layout high-end complex formulation technology platform, inhalation formulation platform stands out

In April 2019, Shutalin ® The first generic of compound ipratropium bromide inhalation solution has been approved for marketing, becoming the first inhalation preparation approved for marketing since the national generic drug consistency evaluation;
As of April 2022, Jiankangyuan has been approved to launch 5 varieties covering 4 categories and a total of 9 product specifications, establishing its leading position in domestic inhalation formulations.

As of October 2022, 7 varieties of Jiankangyuan have been approved for listing, covering 4 categories and a total of 11 product specifications.

2010-2015

Active participation in biomedical and layout of Internet One Health industry

In 2010, Monoclonal Antibody Biology Co., Ltd. was established. In the same year, it joined the TNC Greater China Council. It actively utilized the company's superior resources, integrated resources and participated in the natural environmental protection work. In 2015, it laid out the Internet Medical One Health industry.

2002-2003

The Group covered dual-listed companies through expansion and acquisition

In 2002, it acquired Livzon Pharmaceutical Group; in 2003, it was renamed Joincare Pharmaceutical Group Industry Co., Ltd.

2001-2002

Landing in the capital market

1995-1997

Successful transformation

In 1995, the company realized the strategic transformation and entered the pharmaceutical industry, and changed its name to “Shenzhen Taitai Pharmaceutical Industry Co., Ltd.”;

In 1997, the company acquired Shenzhen Haibin Pharmaceutical Co., Ltd., completing the successful transformation from a health product company to a pharmaceutical company.

1992-1994

Establishment in the South

In 1992, Shenzhen Aimier Food Co., Ltd., the predecessor of Joincare Pharmaceutical Group Industry Co., Ltd., was established;

In 1993, the first brand for women “Taitai Oral Liquid” was successfully launched, creating the era of women's health products and laying a foundation of the company’s leading position in the health products industry.

In 1994, the company changed its name to “Shenzhen Taitai Health Food Co., Ltd.”;